5 - 7 days
NRAS is a guanosine triphosphate (GTP)-binding protein involved in downstream receptor signaling, which is critical for cell proliferation, survival, and differentiation. Mutations in the NRAS oncogene are frequently found in human cancers. They are common in melanomas, colorectal cancer, and thyroid cancer. This assay detects NRAS mutations in exons 2, 3, and 4, allowing the determination of drug response.
Provide a copy of the pathology report; the NRAS test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 800-345-4363.
This assay is able to detect 5% mutation in a background of wild-type DNA. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
SNaPshot Multiplex PCR (primer extension-based method)
Information on collection, storage, and volume
Formalin-fixed, paraffin-embedded (FFPE) tissue or slides.
Formalin-fixed, paraffin-embedded tissue block or four unstained slides and one matching H&E-stained slide at 5 μM.
Two unstained slides and one matching H&E-stained slide at 5 μM. Samples with >4mm² and ≥50% tumor content are preferred.
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks or slides
Maintain blocks/slides at room temperature.
Tumor block containing insufficient tumor tissue; broken or stained slides
Find more tests related to this one.